Clinical Trials Logo

Tumor clinical trials

View clinical trials related to Tumor.

Filter by:

NCT ID: NCT00463814 Active, not recruiting - Cancer Clinical Trials

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies

Start date: March 8, 2007
Phase: Phase 1
Study type: Interventional

The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in patients with advanced solid malignancies.

NCT ID: NCT00413322 Completed - Tumor Clinical Trials

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

Start date: September 2005
Phase: Phase 1
Study type: Interventional

This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves within the body when given with 5-Fluorouracil (5-FU).

NCT ID: NCT00381654 Terminated - Tumor Clinical Trials

Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies

Start date: October 2006
Phase: Phase 1
Study type: Interventional

AV-412 is a new oral therapy developed to inhibit the growth of solid tumors in patients who have not responded to standard therapy or surgical interventions, or who have experienced relapse. This study will test the safety of AV-412 and determine the maximum tolerated dose for the treatment of solid tumors.

NCT ID: NCT00329004 Completed - Cancer Clinical Trials

A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors

Start date: August 2006
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to determine the highest dose of the drug (BMS-690514) that can be safely given to patients with advanced cancer.

NCT ID: NCT00302172 Completed - Cancer Clinical Trials

ARQ 197 in Subjects With Metastatic Solid Tumors

Start date: January 2006
Phase: Phase 1
Study type: Interventional

To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.

NCT ID: NCT00152659 Completed - Epilepsy Clinical Trials

Developing Criteria for Cortical Resections

Start date: September 1, 1998
Phase:
Study type: Observational

The purpose of this study is to study how disease processes like tumors or epilepsy spread in the brain.

NCT ID: NCT00113438 Completed - Cancer Clinical Trials

Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors

Start date: March 2005
Phase: Phase 2
Study type: Interventional

This is a study evaluating the safety and effectiveness of Combretastatin A4 Phosphate (CA4P) combined with the chemotherapy drugs, carboplatin and paclitaxel. The full treatment and observation time should be about 5 months. During this time the patient should receive 18 CA4P infusions and 6 carboplatin followed by paclitaxel treatments. Patients will be randomized into one of two CA4P dose-level groups in order to recommend a preferred dose-level for future studies. At least 2 dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) scans will be conducted to monitor the blood flow through the tumor before and after treatment with CA4P.

NCT ID: NCT00027326 Enrolling by invitation - Cancer Clinical Trials

Collection of Blood and Urine From Patients Undergoing Radiation Therapy

Start date: December 2, 2001
Phase:
Study type: Observational

Background: -Research in NCI's Radiation Oncology Branch depends on the availability of blood and urine samples from patients receiving radiation therapy. Objectives: -To explore the effects of radiation therapy on gene expression in white blood cells, to measure radiation damage in red blood cells and to examine changes in hormone levels in the blood and urine after radiation therapy. Eligibility: -Patients 18 years of age and older who are receiving radiation therapy. Design: - Blood and urine samples are collected when participants enter the study. - Additional samples may be collected at different times during and after treatment. Ideally, samples are obtained before, at the completion of, and 1 month following radiation therapy. Blood samples usually will be collected during routine patient monitoring procedures and will not require an additional needle stick. - A total of 300 patients will be studied at the NCI in Bethesda, MD, Johns Hopkins University in Baltimore and the University of Pennsylvania in Philadelphia.